Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This month tags : Positive save search
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ACRV | $9.46 -3.67% -3.81% 300K
|
| Email alert
Add to watchlist
acr-368 positive pipeline for program therapeutics today
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CAPR | $5.04 4.56% 4.37% 910K
|
Health Technology
|
| O: 9.13%
H: 7.41%
C: -4.18%
cap-1002 fda positive program therapeutics duchenne type-b meeting
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: 4.42%
H: 3.11%
C: -9.89%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CYTO | $1.495 -5.38% -5.69% 3M
|
Manufacturing
|
| O: 1.27%
H: 0.0%
C: -10.0%
positive publication bentrio trial therapeutics results
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
IMMP | $2.59 3.19% 3.09% 1.4M
|
Health Technology
|
| O: 14.4%
H: 8.99%
C: -6.83%
tacti-003 positive topline results
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
NVNO | $5.27 -4.18% -4.36% 100K
|
Manufacturing
|
| O: 9.8%
H: 0.0%
C: -6.79%
symposium positive topline trial today
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.15 -0.13% -0.13% 420K
|
Health Technology
|
| O: 1.03%
H: 0.72%
C: -0.13%
positive treatment global for
Argentina Lithium Announces Positive Lithium Values in the 12th Exploration Well at the Rincon West Project
Published: 2024-04-24 (Crawled : 11:00) - prnewswire.com
STLA | $24.86 -0.4% 0.2% 5.3M
|
Manufacturing
|
| O: 0.32%
H: 0.2%
C: -0.36%
west lithium positive
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Published: 2024-04-24 (Crawled : 11:00) - hancockjaffe.com
NVNO | $5.27 -4.18% -4.36% 100K
|
Manufacturing
|
| O: 9.8%
H: 0.0%
C: -6.79%
venovalve symposium positive topline trial today
Calliditas Announces Positive NefIgArd Open Label Extension Results
Published: 2024-04-24 (Crawled : 08:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 3.46%
H: 0.0%
C: -1.75%
label positive nefigard extension results
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.36%
H: 0.05%
C: -0.15%
malaria positive treatment for novartis
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K
|
Health Technology
|
| O: 5.49%
H: 2.84%
C: -0.65%
nbi-1065 positive for
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
SILO | $1.9 6.74% 6.32% 380K
|
Finance and Insurance
|
| O: 9.18%
H: 0.47%
C: -16.82%
pharma positive treatment for results
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
Published: 2024-04-23 (Crawled : 11:00) - globenewswire.com
TOVX | News | $0.3686 -2.2% 0.27% 120K
|
Manufacturing
|
| O: 2.44%
H: 0.0%
C: -9.52%
vcn-01 positive topline trial
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Published: 2024-04-22 (Crawled : 13:00) - globenewswire.com
ASLN | News | $0.4863 3.69% 3.56% 1M
|
Health Technology
|
| O: 13.73%
H: 5.17%
C: -20.69%
dermatitis positive pharmaceuticals results study
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M
|
Health Technology
|
| O: -6.86%
H: 6.89%
C: 4.6%
positive trial results
Vision Sensing Acquisition Corp. Receives Positive Ruling from Nasdaq Hearings Panel
Published: 2024-04-19 (Crawled : 19:00) - globenewswire.com
VSAC | $11.13 0.0% 24K
|
n/a
| Email alert
Add to watchlist
nasdaq positive acquisition vision
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Published: 2024-04-18 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K
|
|
| O: -0.63%
H: 1.89%
C: -4.4%
neurology presentation readout positive topline meeting
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.75 -1.6% -1.63% 66K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.